| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
110.03(B) |
| Last
Volume: |
750,617 |
Avg
Vol: |
759,306 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
255,165 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$247,812,013 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
43 |
67 |
128 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stahl Neil |
EVP Research and Development |
• – – |
2015-11-06 |
4 |
S |
$562.37 |
$11,260,068 |
D/D |
(20,000) |
44,130 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2015-11-05 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
17,349 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
D |
$567.63 |
$32,865,209 |
D/D |
(57,899) |
64,130 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
OE |
$21.25 |
$2,828,500 |
D/D |
100,000 |
78,377 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2015-11-03 |
4 |
AS |
$580.23 |
$2,312,217 |
D/D |
(3,985) |
351,851 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2015-11-02 |
4 |
GA |
$0.00 |
$0 |
I/I |
43,348 |
612,936 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2015-11-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
43,348 |
500,000 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2015-11-02 |
4 |
AS |
$580.18 |
$7,691,446 |
D/D |
(13,257) |
355,836 |
|
- |
|
| Yancopoulos George |
President Regeneron Laboratori |
• • – |
2015-11-02 |
4 |
AS |
$561.75 |
$24,778,125 |
D/D |
(43,348) |
543,348 |
|
- |
|
| Yancopoulos George |
President Regeneron Laboratori |
• • – |
2015-10-30 |
4 |
D |
$559.08 |
$53,739,888 |
D/D |
(96,122) |
586,696 |
|
- |
|
| Yancopoulos George |
President Regeneron Laboratori |
• • – |
2015-10-30 |
4 |
OE |
$11.64 |
$2,128,002 |
D/D |
182,818 |
682,818 |
|
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2015-10-06 |
4 |
B |
$470.41 |
$5,214,519 |
I/I |
11,040 |
23,108,570 |
1.5 |
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2015-10-06 |
4 |
B |
$449.14 |
$37,024,197 |
I/I |
80,538 |
23,097,530 |
1.5 |
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2015-10-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
455 |
153,935 |
|
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2015-09-23 |
4 |
B |
$523.43 |
$78,708,570 |
I/I |
147,209 |
23,016,992 |
1.5 |
- |
|
| Brown Michael S |
Director |
– • – |
2015-09-21 |
4 |
AS |
$551.55 |
$1,654,650 |
D/D |
(3,000) |
0 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2015-09-21 |
4 |
OE |
$57.11 |
$171,330 |
D/D |
3,000 |
3,000 |
|
- |
|
| Baker Charles A |
Director |
– • – |
2015-09-17 |
4 |
AS |
$550.00 |
$2,750,000 |
D/D |
(5,000) |
9,000 |
|
- |
|
| Baker Charles A |
Director |
– • – |
2015-09-17 |
4 |
OE |
$18.61 |
$93,050 |
D/D |
5,000 |
14,000 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2015-09-02 |
4 |
D |
$506.37 |
$3,294,950 |
D/D |
(6,507) |
42,806 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2015-09-02 |
4 |
OE |
$402.69 |
$2,909,838 |
D/D |
7,226 |
49,313 |
|
- |
|
| Larosa Joseph J |
SVP General Counsel and Secret |
• – – |
2015-09-01 |
4 |
OE |
$59.20 |
$99,989 |
D/D |
1,689 |
16,756 |
|
- |
|
| Powchik Peter |
SVP Clinical Development & Reg |
• – – |
2015-08-14 |
4 |
S |
$569.63 |
$13,465,866 |
D/D |
(23,485) |
15,821 |
|
- |
|
| Powchik Peter |
SVP Clinical Development & Reg |
• – – |
2015-08-13 |
4 |
D |
$579.35 |
$21,364,111 |
D/D |
(36,876) |
39,306 |
|
- |
|
| Powchik Peter |
SVP Clinical Development & Reg |
• – – |
2015-08-13 |
4 |
OE |
$30.63 |
$7,082,070 |
D/D |
60,361 |
41,702 |
|
- |
|
2430 Records found
|
|
Page 48 of 98 |
|
|
0.17 (0.02%) 
